470 results on '"Corso, Alessandro"'
Search Results
2. Incidence and clinical progression of asymptomatic peripherally inserted central catheter–related thrombosis in solid neoplasm patients: ultrasound insights from a prospective cohort study
3. Lives at the border : abandonment and survival at the frontier of Lampedusa
4. Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel
5. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
6. Incidence and Clinical Progression of Asymptomatic PICC-Related Thrombosis in Solid Neoplasm Patients: Ultrasound Insights from a Prospective Cohort Study
7. Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia
8. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
9. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
10. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
11. Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations
12. Disorganization and real-world functioning in schizophrenia: Results from the multicenter study of the Italian Network for Research on Psychoses
13. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
14. The Economic Burden of Multiple Myeloma. Definition of a Model for Forecasting Patients’ Costs
15. Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)
16. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity
17. Experts’ consensus on the definition and management of high risk multiple myeloma
18. Daylight Autonomy as a Driver for Office Building Retrofitting
19. The smell of bare death: Encountering life at the graveyard of Lampedusa.
20. Judgment, Doubt, and Self-Doubt: A Reflexive Turn from the Borderland of Lampedusa
21. The smell of bare death: Encountering life at the graveyard of Lampedusa
22. The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study
23. Interactive directional subsurface scattering and transport of emergent light
24. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström's macroglobulinemia and related lymphoid neoplasms
25. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
26. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice
27. Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients
28. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
29. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
30. Immune-mediated neuropathies in myeloma patients treated with bortezomib
31. The place of thalidomide in the treatment of multiple myeloma
32. What if we could step in the shoes of migrants and inhabitants on the island of Lampedusa?
33. Monoclonal gammopathy of undetermined significance: a new proposal of workup
34. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
35. Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma
36. Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma
37. Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: a single center experience
38. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
39. Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement
40. Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
41. Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma
42. Resolution of invasive fungal sinusitis in immunocompromised patients: neutrophil count is crucial beside a combined medical and surgical approach
43. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
44. Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse
45. Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant
46. Pomalidomide + Bortezomib + Dexamethasone After One Prior Line of Therapy in Bortezomib-Pretreated Multiple Myeloma: Subanalysis of OPTIMISMM
47. Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived
48. Changing pattern of presentation in monoclonal gammopathy of undetermined significance: a single-center experience with 1400 patients
49. Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients
50. Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.